"Neurotransmitter Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function.
| Descriptor ID |
D018377
|
| MeSH Number(s) |
D27.505.519.625 D27.505.696.577
|
| Concept/Terms |
Neurotransmitters- Neurotransmitters
- Transmitter Substances, Nerve
- Substances, Nerve Transmitter
- Nerve Transmitter Substances
- Neurotransmitter
|
Below are MeSH descriptors whose meaning is more general than "Neurotransmitter Agents".
Below are MeSH descriptors whose meaning is more specific than "Neurotransmitter Agents".
This graph shows the total number of publications written about "Neurotransmitter Agents" by people in this website by year, and whether "Neurotransmitter Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 2 | 3 |
| 2004 | 2 | 2 | 4 |
| 2005 | 1 | 2 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 4 | 4 |
| 2009 | 2 | 0 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 2 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 4 | 4 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neurotransmitter Agents" by people in Profiles.
-
Gollion C, De Icco R, Dodick DW, Ashina H. The premonitory phase of migraine is due to hypothalamic dysfunction: revisiting the evidence. J Headache Pain. 2022 Dec 13; 23(1):158.
-
Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF. Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review. Headache. 2020 07; 60(7):1259-1272.
-
Wu M, White HV, Boehm BA, Meriney CJ, Kerrigan K, Frasso M, Liang M, Gotway EM, Wilcox MR, Johnson JW, Wipf P, Meriney SD. New Cav2 calcium channel gating modifiers with agonist activity and therapeutic potential to treat neuromuscular disease. Neuropharmacology. 2018 03 15; 131:176-189.
-
Yuan H, Silberstein SD. Histamine and Migraine. Headache. 2018 01; 58(1):184-193.
-
Ozdemir T, Srinivasan PP, Zakheim DR, Harrington DA, Witt RL, Farach-Carson MC, Jia X, Pradhan-Bhatt S. Bottom-up assembly of salivary gland microtissues for assessing myoepithelial cell function. Biomaterials. 2017 Oct; 142:124-135.
-
Maasumi K, Tepper SJ, Rapoport AM. New treatments for headache. Neurol Sci. 2017 May; 38(Suppl 1):145-156.
-
Kumar P, Tripathi SK, Chen CP, Mehta N, Paudyal B, Wickstrom E, Thakur ML. Evaluation of a PACAP Peptide Analogue Labeled with (68)Ga Using Two Different Chelating Agents. Cancer Biother Radiopharm. 2016 Feb; 31(1):29-36.
-
Anderson WD, Makadia HK, Vadigepalli R. Molecular variability elicits a tunable switch with discrete neuromodulatory response phenotypes. J Comput Neurosci. 2016 Feb; 40(1):65-82.
-
Goldberg SW, Nahas SJ. Supratrochlear and Supraorbital Nerve Stimulation for Chronic Headache: a Review. Curr Pain Headache Rep. 2015 Jul; 19(7):26.
-
Gu H, Lazarenko RM, Koktysh D, Iacovitti L, Zhang Q. A Stem Cell-Derived Platform for Studying Single Synaptic Vesicles in Dopaminergic Synapses. Stem Cells Transl Med. 2015 Aug; 4(8):887-93.